Table 3.
Validation primer sets.
| Target | Sequence location (NT)a | Primers | Sequence 5’–3’ | Amplicon length (bp) |
|---|---|---|---|---|
| BNT162b2 | 60 | Forward | CAGAACACAGCTGCCTCCAG | 503 |
| Reverse | TTCTTGAAGTTGCCCTGCTT | |||
| 416 | Forward | CCAACGTGGTCATCAAAGTG | 1128 | |
| Reverse | AAGCTCAGCACCACCACTCT | |||
| 2969 | Forwardb | GGTGCAGATCGACAGACTGA | 682 | |
| Reverse | CAGATGTACCAGGGCCACTT | |||
| mRNA-1273 | 160 | Forward | CTGTTCCTGCCCTTCTTCAGC | 405 |
| Reverse | GGTTCTTGAAGTTGCCCTGCTTG |
aSequence location is numbered in relation to the start codon of the vaccine’s signal peptide segment.
bForward primer is the same as for the assay. The reverse primer extends 480 NTs past the dsDNA control.